• Resources
  • Blog
  • Journalists
  • Log In
  • Sign Up
  • Data Privacy
  • Send a Release
Cision PR Newswire: news distribution, targeting and monitoring home
  • News
  • Products
    • Overview
    • Distribution by PR Newswire
    • Cision Communications Cloud®
    • Cision IR
    • Sponsored Placement
    • All Products
  • Contact
    • General Inquiries
    • Request a Demo
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices

 

When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • All Public Company
      • English-only
      • News Releases Overview

      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
      • Multimedia Gallery Overview

      • Trending Topics

      • All Trending Topics
  • Business & Money
      • Auto & Transportation

      • All Automotive & Transportation
      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • Auto & Transportation Overview

      • View All Auto & Transportation

      • Business Technology

      • All Business Technology
      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • Business Technology Overview

      • View All Business Technology

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Financial Services & Investing

      • All Financial Services & Investing
      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • Financial Services & Investing Overview

      • View All Financial Services & Investing

      • General Business

      • All General Business
      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • General Business Overview

      • View All General Business

  • Science & Tech
      • Consumer Technology

      • All Consumer Technology
      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • Consumer Technology Overview

      • View All Consumer Technology

      • Energy & Natural Resources

      • All Energy
      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • Energy & Natural Resources Overview

      • View All Energy & Natural Resources

      • Environ­ment

      • All Environ­ment
      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • Environ­ment Overview

      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • All Heavy Industry & Manufacturing
      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • Heavy Industry & Manufacturing Overview

      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • All Telecomm­unications
      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • Telecomm­unications Overview

      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • All Consumer Products & Retail
      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • Consumer Products & Retail Overview

      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Health

      • All Health
      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • Health Overview

      • View All Health

      • Sports

      • All Sports
      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • Sports Overview

      • View All Sports

      • Travel

      • All Travel
      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • Travel Overview

      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • All Policy & Public Interest
      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • Policy & Public Interest Overview

      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • All People & Culture
      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • People & Culture Overview

      • View All People & Culture

      • In-Language News

      • español
      • português
      • Česko
      • Danmark
      • Deutschland
      • España
      • France
      • Italia
      • Nederland
      • Norge
      • Polska
      • Portugal
      • Россия
      • Slovensko
      • Suomi
      • Sverige
  • Overview
  • Distribution by PR Newswire
  • Cision Communications Cloud®
  • Cision IR
  • Sponsored Placement
  • All Products
  • General Inquiries
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • PR Newswire: news distribution, targeting and monitoring
  • Send a Release
    • ALL CONTACT INFO
    • Contact Us

      888-776-0942
      from 8 AM - 10 PM ET

  • Send a Release
  • Sign Up
  • Log In
  • Resources
  • Blog
  • Journalists
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
    • Trending Topics
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign Up
  • Log In
  • Resources
  • Blog
  • Journalists
  • RSS
  • GDPR
  • Overview
  • Distribution by PR Newswire
  • Cision Communications Cloud®
  • Cision IR
  • All Products
  • Send a Release
  • Sign Up
  • Log In
  • Resources
  • Blog
  • Journalists
  • RSS
  • GDPR
  • General Inquiries
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Send a Release
  • Sign Up
  • Log In
  • Resources
  • Blog
  • Journalists
  • RSS
  • GDPR

PharmaPoint: Osteoporosis - US Drug Forecast and Market Analysis to 2022


News provided by

Reportlinker

Apr 10, 2013, 08:53 ET

Share this article

Share this article


NEW YORK, April 10, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

PharmaPoint: Osteoporosis - US Drug Forecast and Market Analysis to 2022
http://www.reportlinker.com/p01158411/PharmaPoint-Osteoporosis---US-Drug-Forecast-and-Market-Analysis-to-2022.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication

PharmaPoint: Osteoporosis - US Drug Forecast and Market Analysis to 2022

Summary

GlobalData has released its new Country report, "PharmaPoint: Osteoporosis - US Drug Forecast and Market Analysis to 2022". Despite its maturity, the osteoporosis market is expected to undergo substantial change between 2012 and 2022. Most importantly, the 'gold-standard' bisphosphonates will lose patent protection by end-of-year 2013, flooding the marketplace with less expensive generic versions of these physician-preferred medications. Additionally, Eli Lilly's blockbuster Evista, the only available SERM in the US, will lose patent protection in 2014, flooding the market with yet more affordable generic options. Also during the forecast period covered by this report, osteoporosis drug development research will lead to the launches of a wave of novel anabolic drugs with greater efficacy and safety, causing a major market shift away from anti-resorptive drugs. The number of companies vying for patient share will shrink by as much as 50%, as established players exit the market or acquire smaller players. Lastly, the aging of the population in developed markets will result in a larger patient pool.

These changes in the osteoporosis market will be reflected in the slow growth during the forecast period, with the market growing from $6 billion to $8 billion in 2011 USD at a CAGR of 3%.

The large dip in sales caused by these expiries is offset by six pipeline product launches over the forecast period, with three of these being potential blockbuster drugs. This next generation of drugs typically consists of biologics and will be higher priced than the drugs losing patent protection in the first half of the forecast period.

Scope

- Overview of the Osteoporosis including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in the US including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in the US from 2012-2022.
- Analysis of the impact of key events as well the drivers and restraints affecting the US Osteoporosis market.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Osteoporosis
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of drug performance
- Obtain sales forecast for drugs from 2012-2022 in the US

Table of Contents

1 Table of Contents 4
1.1 List of Tables 7
1.2 List of Figures 9
2 Introduction 10
2.1 Catalyst 10
2.2 Related Reports 10
3 Disease Overview 13
3.1 Etiology and Pathophysiology 13
3.1.1 Etiology 13
3.1.2 Pathophysiology 16
3.1.3 Risk Factors 17
3.1.4 Quality of Life 17
3.2 Symptoms 18
4 Disease Management 19
4.1 Treatment Overview 19
4.1.1 Diagnosis and Referral 19
4.1.2 Treatment Guidelines 20
4.1.3 Disease Management 22
4.2 United States 25
4.2.1 Diagnosis 25
4.2.2 Clinical Practice 26
5 Competitive Assessment 27
5.1 Overview 27
5.2 Strategic Competitor Assessment 27
5.3 Product Profiles – Major Brands 31
5.3.1 Actonel (risedronate sodium) 31
5.3.2 Evista (raloxifene hydrochloride) 34
5.3.3 Reclast (zolendronic acid) 37
5.3.4 Forteo (teriparatide) 40
5.3.5 Prolia (denosumab) 44
5.3.6 Protelos (strontium ranelate) 47
5.3.7 Miacalcin and Fortical (calcitonin-salmon) 50
5.3.8 Viviant/Conbriza (bazedoxifene) 54
5.3.9 Recalbon/Bonoteo (minodronic acid hydrate) 57
5.3.10 Alendronate sodium 60
5.3.11 Ibandronate 61
6 Opportunity and Unmet Need 63
6.1 Overview 63
6.2 Unmet Needs 64
6.2.1 Disease Awareness and Early Diagnosis 64
6.2.2 Patient Compliance 65
6.2.3 Efficacy 66
6.2.4 Safety 67
6.2.5 Treatment Cost 67
6.2.6 Earlier Intervention 68
6.3 Unmet Needs Gap Analysis 69
6.4 Opportunity 1: Dual-Action Therapies 70
6.5 Opportunity 2: Osteoporosis Prevention Therapies 71
6.6 Opportunity 3: Dosing and Administration 72
7 Pipeline Assessment 73
7.1 Overview 73
7.2 Promising Drugs in Clinical Development 74
7.2.1 Aprela (bazedoxifene and conjugated estrogens) 76
7.2.2 Romosozumab (AMG-785) 82
7.2.3 Odanacatib 88
7.2.4 BA-058 94
7.2.5 PTH(1-31)NH2 99
7.2.6 Ostora (recombinant salmon calcitonin) 104
8 Market Outlook 109
8.1 United States 109
8.1.1 Forecast 109
8.1.2 Key Events 112
8.1.3 Drivers and Barriers 112
9 Appendix 115
9.1 Bibliography 115
9.2 Abbreviations 122
9.3 Methodology 125
9.4 Forecasting Methodology 125
9.4.1 Diagnosed Osteoporosis Patients 125
9.4.2 Percent Drug-Treated Patients 125
9.4.3 Drugs Included in Each Therapeutic Class 126
9.4.4 Launch and Patent Expiry Dates 126
9.4.5 General Pricing Assumptions 127
9.4.6 Individual Drug Assumptions 127
9.4.7 Generic Erosion 132
9.4.8 Pricing of Pipeline Agents 132
9.5 Physicians and Specialists Included in this Study 133
9.5.1 About the Authors 134
9.5.2 Global Head of Healthcare 135
9.6 About GlobalData 136
9.7 Contact Us 136
9.8 Disclaimer 136

List of Tables

Table 1: Etiology of Primary Osteoporosis 13
Table 2: Etiology of Secondary Osteoporosis 15
Table 3: Symptoms of Osteoporosis 18
Table 4: Diagnostic Tests for Osteoporosis 19
Table 5: T-Score Ranges for Determination of BMD 20
Table 6: Treatment Guidelines for Osteoporosis 21
Table 7: Most Prescribed Drugs for Osteoporosis by Therapeutic Class in the Global Markets, 2012 23
Table 8: Leading Treatments for Osteoporosis, 2012 30
Table 9: Product Profile – Actonel 32
Table 10: Actonel SWOT Analysis, 2012 33
Table 11: Product Profile – Evista 35
Table 12: Evista SWOT Analysis, 2012 36
Table 13: Product Profile – Reclast 38
Table 14: Reclast SWOT Analysis, 2012 39
Table 15: Product Profile – Forteo 41
Table 16: Mean Percent Change from Baseline in BMD with Forteo vs. Placebo in Postmenopausal Women with Osteoporosis 42
Table 17: Forteo SWOT Analysis, 2012 43
Table 18: Product Profile – Prolia 44
Table 19: Prolia SWOT Analysis, 2012 46
Table 20: Product Profile – Protelos 47
Table 21: Protelos SWOT Analysis, 2012 48
Table 22: Product Profile – Miacalcin and Fortical Nasal Spray 51
Table 23: Adverse Events with Miacalcin Nasal Spray 51
Table 24: Miacalcin and Fortical Nasal Spray SWOT Analysis, 2012 52
Table 25: Product Profile – Viviant/Conbriza 54
Table 26: Viviant/Conbriza SWOT Analysis, 2012 56
Table 27: Product Profile – Recalbon/Bonoteo 57
Table 28: Recalbon/Bonoteo SWOT Analysis, 2012 58
Table 29: Overall Unmet Needs – Current Level of Attainment 63
Table 30: Clinical Unmet Needs – Gap Analysis, 2012 69
Table 31: Osteoporosis – Pipeline, 2012 74
Table 32: Comparison of Therapeutic Classes in Development for Osteoporosis, 2012 74
Table 33: Product Profile – Aprela 77
Table 34: Aprela SWOT Analysis, 2012 80
Table 35: Product Profile – Romosozumab 82
Table 36: Romosozumab SWOT Analysis, 2012 86
Table 37: Product Profile – Odanacatib 88
Table 38: Odanacatib SWOT Analysis, 2012 92
Table 39: Product Profile – BA-058 94
Table 40: BA-058 SWOT Analysis, 2012 97
Table 41: Product Profile – PTH(1-31)NH2 99
Table 42: PTH(1-31)NH2 SWOT Analysis, 2012 102
Table 43: Product Profile – Ostora 105
Table 44: Ostora SWOT Analysis, 2012 107
Table 45: US Sales Forecasts ($m) for Osteoporosis, 2012-2022 110
Table 46: Key Events Impacting Sales for Osteoporosis in the US, 2012–2022 112
Table 47: Osteoporosis Market – Drivers and Barriers in the United States, 2012–2022 112
Table 48: Key Launch Dates 126
Table 49: Key Patent Expiries 126
Table 50: Number of High-Prescribing Physicians Surveyed 133

List of Figures

Figure 1: Company Portfolio Gap Analysis in Osteoporosis, 2012–2022 75
Figure 2: Sales for Osteoporosis Drugs in the United States by Drug Class, 2012–2022 111

To order this report:
Drug_and_Medication Industry:
PharmaPoint: Osteoporosis - US Drug Forecast and Market Analysis to 2022

__________________________
Contact Clare: [email protected]
US:(339) 368 6001
Intl:+1 339 368 6001

SOURCE Reportlinker

Modal title

Contact Cision

  • Cision Distribution 888-776-0942
    from 8 AM - 9 PM ET

  • Chat with an Expert
  • General Inquiries
  • Request a Demo
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices

Products

  • Cision Communication Cloud®
  • For Marketers
  • For Public Relations
  • For IR & Compliance
  • For Agency
  • For Small Business
  • All Products

About

  • About PR Newswire
  • About Cision
  • Become a Publishing Partner
  • Become a Channel Partner
  • Careers
  • COVID-19 Resources
  • Accessibility Statement
  • Asia
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Israel
  • Italy
  • Mexico
  • Middle East
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom

My Services

  • All New Releases
  • Online Member Center
  • ProfNet

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2022 Cision US Inc.